Companies 0 See All

Hedge Funds 0 See All

Insiders 0 See All

Institutional Investors 0 See All

Click here to see all results for

Home > Insider Trading > Filing (0001562180-24-002430)

Filing Details

Accession Number:: 0001562180-24-002430
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2024-03-07 18:05:43
Reporting Period:: 2024-03-05

Accepted Time:: 2024-03-07 18:05:43
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1590877	Regenxbio Inc.	RGNX	Biological Products, (No Disgnostic Substances) (2836)	471851754

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1700659	Steve Pakola	C/O Regenxbio Inc. 9804 Medical Center Drive Rockville MD 20850	Chief Medical Officer	No	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2024-03-05	12,878	$22.25	120,070	No	4	M	Direct
Common Stock	Disposition	2024-03-05	12,878	$28.36	107,192	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Options (Right to Buy)	Disposition	2024-03-05	12,878	$0.00	12,878	$22.25

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
31,277		2033-01-03	No	4	M	Direct

Footnotes

This transaction was effected pursuant to a Rule 10b5-1 trading plan.
The previously granted option, representing a right to purchase a total of 44,155 shares, became exercisable as follows: 25% of the shares subject to this option vested on January 3, 2024, and the balance vests in equal monthly installments over the 36 months thereafter while the optionee provides continuous service to the Issuer